MEFOXIN SUMMARY
MEFOXIN®
(CEFOXITIN INJECTION)
PREMIXED INTRAVENOUS SOLUTION
MEFOXIN (Cefoxitin for Injection) is a semi-synthetic, broad-spectrum cepha antibiotic sealed under nitrogen for intravenous administration. It is derived from cephamycin C, which is produced by
Streptomyces lactamdurans.
MEFOXIN is indicated for the following:
Treatment
MEFOXIN is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below.
- Lower respiratory tract infections, including pneumonia and lung abscess, caused by
Streptococcus pneumoniae,
other streptococci (excluding enterococci, e.g., Enterococcus faecalis
[formerly
Streptococcus faecalis
]),
Staphylococcus aureus
(including penicillinase-producing strains), Escherichia coli, Klebsiella
species,
Haemophilus influenzae,
and
Bacteroides
species.
- Urinary tract infections caused by
Escherichia coli, Klebsiella
species,
Proteus mirabilis, Morganella morganii, Proteus vulgaris
and
Providencia
species (including
P. rettgeri).
- Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by
Escherichia coli, Klebsiella
species,
Bacteroides
species including
Bacteroides fragilis, and
Clostridium
species.
- Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by
Escherichia coli, Neisseria gonorrhoeae
(including penicillinase-producing strains), Bacteroides
species including
B. fragilis,
Clostridium
species,
Peptococcus niger,
Peptostreptococcus
species, and
Streptococcus agalactiae. MEFOXIN, like cephalosporins, has no activity against
Chlamydia trachomatis.
Therefore, when MEFOXIN is used in the treatment of patients with pelvic inflammatory disease and
C. trachomatis
is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added.
- Septicemia caused by
Streptococcus pneumoniae, Staphylococcus aureus
(including penicillinase-producing strains), Escherichia coli, Klebsiella
species, and
Bacteroides
species including
B. fragilis.
- Bone and joint infections caused by
Staphylococcus aureus
(including penicillinase-producing strains).
- Skin and skin structure infections caused by
Staphylococcus aureus
(including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes
and other streptococci (excluding enterococci e.g., Enterococcus faecalis
[formerly
Streptococcus faecalis
]),
Escherichia coli, Proteus mirabilis, Klebsiella
species,
Bacteroides
species including
B. fragilis,
Clostridium
species,
Peptococcus niger,
and
Peptostreptococcus
species.
Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to MEFOXIN. Therapy may be started while awaiting the results of these studies.
In randomized comparative studies, MEFOXIN and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. MEFOXIN has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases.
Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to MEFOXIN. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with MEFOXIN. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with MEFOXIN.
Prevention
MEFOXIN is indicated for the prophylaxis of infection in patients undergoing uncontaminated gastrointestinal surgery, vaginal hysterectomy, abdominal hysterectomy, or cesarean section.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism so that appropriate treatment may be instituted.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of MEFOXIN and other antibacterial drugs, MEFOXIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
|
